TSVT(Delisted)
2seventy bio·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 2
Significant Revenue Decline
EPS Beats Expectation
FDA Approved
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TSVT
2seventy Bio, Inc.
A leading immuno-oncology cell therapy company that develops gene,cell therapies and oncology roots for cancer and severe genetic diseases
60 Binney Street
, Cambridge
, Massachusetts 02142
--
2seventy bio, Inc., was incorporated in Delaware on April 26, 2021. The company is a cell and gene therapy company focused on the research, development and commercialization of cancer translational therapies. The company is advancing several preclinical and clinical programs in oncology and, together with their partner Bristol-Myers Squibb (Bristol-Myers Squibb), is providing Abecma, including immunomodulators, proteasome inhibitors and anti-CD38 monoclonal antibodies, to multiple myeloma patients in the United States after approval for at least four prior treatments.
Company Financials
EPS
TSVT has released its 2025 Q1 earnings. EPS was reported at 0.01, versus the expected -0.1, beating expectations. The chart below visualizes how TSVT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TSVT has released its 2025 Q1 earnings report, with revenue of 22.94M, reflecting a YoY change of 84.46%, and net profit of 482.00K, showing a YoY change of 100.92%. The Sankey diagram below clearly presents TSVT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
